Development of potent and selective tissue transglutaminase inhibitors: Their effect on TG2 function and application in pathological conditions

Chemistry and Biology

Volumn 22, Issue 10, 2015, Pages 1347-1361

  Badarau, Eduard ^a,d   Wang, Zhuo ^a   Rathbone, Dan L ^a   Costanzi, Andrea ^a   Thibault, Thomas ^a   Murdoch, Colin E ^b   El Alaoui, Said ^c   Bartkeviciute, Milda ^b   Griffin, Martin ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c European Institute of Chemistry and Biology ^*  (France)

^d INSTITUT EUROPÉEN DE CHIMIE ET BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE INHIBITOR; ANGIOTENSIN II; COLLAGEN; FIBRONECTIN; GLUTAMATE DEHYDROGENASE; IONOMYCIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; SYNDECAN 4; TISSUE TRANSGLUTAMINASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

3T3 CELL LINE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CELL MEMBRANE PERMEABILITY; CELL MOTILITY; CELL SURFACE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYTOLYSIS; CYTOSOLIC FRACTION; DRUG CONFORMATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; MALE; MOLECULAR DYNAMICS; MOLECULAR MODEL; MOUSE; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYMOLOGY; FIBROSIS; FLUORESCENCE MICROSCOPY; METABOLISM; MOLECULAR LIBRARY; PATHOPHYSIOLOGY; PHARMACOLOGY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME INHIBITORS; FIBROSIS; GTP-BINDING PROTEINS; HUMANS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEPHROSCLEROSIS; NIH 3T3 CELLS; PROTEIN BINDING; SMALL MOLECULE LIBRARIES; SYNDECAN-4; TRANSGLUTAMINASES;

EID: 84950275624     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2015.08.013     Document Type: Article

References (41)

1. Badarau, E., Collighan, R.J., and Griffin, M. (2013a). Recent advances in the development of tissue transglutaminase (TG2) inhibitors. Amino Acids 44, 119-127.
2. Badarau, E., Mongeot, A., Collighan, R.J., Rathbone, D.L., and Griffin, M. (2013b). Imidazolium-based warheads strongly influence activity of water-soluble peptidic transglutaminase inhibitors. Eur. J. Med. Chem. 66, 526-530.
3. Baumgartner, W., Golenhofen, N., Weth, A., Hiiragi, T., Saint, R., Griffin, M., and Drenckhahn, D. (2004). Role of transglutaminase 1 in stabilisation of intercellular junctions of the vascular endothelium. Histochem. Cell Biol. 122, 17-25.
4. Bergamini, C.M., Collighan, R.J., Wang, Z., and Griffin, M. (2011). Structure and regulation of type 2 transglutaminase in relation to its physiological functions and pathological roles. Adv. Enzymol. Relat. Areas Mol. Biol. 78, 1-46.
5. Colak, G., Keillor, J.W., and Johnson, G.V. (2011). Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation. PLoS One 6, e16665.
6. Choi, K., Siegel, M., Piper, J.L., Yuan, L., Cho, E., Strnad, P., Omary, B., Rich, K.M., and Khosla, C. (2005). Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem. Biol. 12, 469-475.
7. Duval, E., Case, A., Stein, R.L., and Cuny, G.D. (2005). Structure-activity relationship study of novel tissue transglutaminase inhibitors. Bioorg. Med. Chem. Lett. 15, 1885-1889.
8. Freund, K.F., Doshi, K.P., Gaul, S.L., Claremon, D.A., Remy, D.C., Baldwin, J.J., Pitzenberger, S.M., and Stern, A.M. (1994). Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 33, 10109-10119.
9. Fukui, M., Kuramoto, K., Yamasaki, R., Shimizu, Y., Itoh, M., Kawamoto, T., and Hitomi, K. (2013). Identification of a highly reactive substrate peptide for transglutaminase 6 and its use in detecting transglutaminase activity in the skin epidermis. FEBS J. 280, 1420-1429.
10. Griffin, M., Casadio, R., and Bergamini, C.M. (2002). Transglutaminases: nature's biological glues. Biochem. J. 368, 377-396.
11. Griffin, M., Mongeot, A., Collighan, R., Saint, R.E., Jones, R.A., Coutts, I.G., and Rathbone, D.L. (2008). Synthesis of potent water-soluble tissue transglutaminase inhibitors. Bioorg. Med. Chem. Lett. 18, 5559-5562.
12. Han, B.G., Cho, J.W., Cho, Y.D., Jeong, K.C., Kim, S.Y., and Lee, B.I. (2010). Crystal structure of human transglutaminase 2 in complex with adenosine triphosphate. Int. J. Biol. Macromol. 47, 190-195.
13. Hand, D., Bungay, P.J., Elliott, B.M., and Griffin, M. (1985). Activation of transglutaminase at calcium levels consistent with a role for this enzyme as a calcium receptor protein. Biosci. Rep. 5, 1079-1086.
14. Hitomi, K., Kitamura, M., and Sugimura, Y. (2009). Preferred substrate sequences for transglutaminase 2: screening using a phage-displayed peptide library. Amino Acids 36, 619-624.
15. Huang, L., Haylor, J.L., Hau, Z., Jones, R.A., Vickers, M.E., Wagner, B., Griffin, M., Saint, R.E., Coutts, I.G., El Nahas, A.M., et al. (2009). Transglutaminase inhibition ameliorates experimental diabetic nephropathy. Kidney Int. 76, 383-394.
16. Johnson, T.S., Fisher, M., Haylor, J.L., Hau, Z., Skill, N.J., Jones, R., Saint, R., Coutts, I., Vickers, M.E., El Nahas, A.M., et al. (2007). Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J. Am. Soc. Nephrol. 18, 3078-3088.
17. Klock, C., Jin, X., Choi, K., Khosla, C., Madrid, P.B., Spencer, A., Raimundo, B.C., Boardman, P., Lanza, G., and Griffin, J.H. (2011). Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg. Med. Chem. Lett. 21, 2692-2696.
18. Klock, C., Herrera, Z., Albertelli, M., and Khosla, C. (2014). Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2. J. Med. Chem. 57, 9042-9064.
19. Kuzmic, P. (1996). Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase. Anal. Biochem. 237, 260-273.
20. Kuzmic, P. (2009). DynaFit-a software package for enzymology. Methods Enzymol. 467, 247-280.
21. Liu, S., Cerione, R.A., and Clardy, J. (2002). Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity. Proc. Natl. Acad. Sci. USA 99, 2743-2747.
22. Lortat-Jacob, H., Burhan, I., Scarpellini, A., Thomas, A., Imberty, A., Vivès, R.R., Johnson, T., Gutierrez, A., and Verderio, E.A. (2012). Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix. J. Biol. Chem. 287, 18005-18017.
23. Murdoch, C.E., Chaubey, S., Zeng, L., Yu, B., Ivetic, A., Walker, S.J., Vanhoutte, D., Heymans, S., Grieve, D.J., Cave, A.C., et al. (2014). Edothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition. J. Am. Coll. Cardiol. 63, 2734-2741.
24. Ozaki, S., Ebisui, E., Hamada, K., Goto, J., Suzuki, A.Z., Terauchi, A., and Mikoshiba, K. (2010). Potent transglutaminase inhibitors, aryl beta-aminoethyl ketones. Bioorg. Med. Chem. Lett. 20, 1141-1144.
25. Ozaki, S., Ebisui, E., Hamada, K., Suzuki, A.Z., Terauchi, A., and Mikoshiba, K. (2011). Potent transglutaminase inhibitors, dithio beta-aminoethyl ketones. Bioorg. Med. Chem. Lett. 21, 377-379.
26. Pardin, C., Pelletier, J.N., Lubell, W.D., and Keillor, J.W. (2008a). Cinnamoyl inhibitors of tissue transglutaminase. J. Org. Chem. 73, 5766-5775.
27. Pardin, C., Roy, I., Lubell, W.D., and Keillor, J.W. (2008b). Reversible and competitive cinnamoyl triazole inhibitors of tissue transglutaminase. Chem. Biol. Drug Des. 72, 189-196.
28. Pavlyukov, M.S., Antipova, N.V., Balashova, M.V., and Shakhparonov, M.I. (2012). Detection of transglutaminase 2 conformational changes in living cell. Biochem. Biophys. Res. Commun. 421, 773-779.
29. Perez Alea, M., Kitamura, M., Martin, G., Thomas, V., Hitomi, K., and El Alaoui, S. (2009). Development of an isoenzyme-specific colorimetric assay for tissue transglutaminase 2 cross-linking activity. Anal. Biochem. 389, 150-156.
30. Pinkas, D.M., Strop, P., Brunger, A.T., and Khosla, C. (2007). Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 5, 2788-2795.
31. Prime, M.E., Andersen, O.A., Barker, J.J., Brooks, M.A., Cheng, R.K., Toogood-Johnson, I., Courtney, S.M., Brookfield, F.A., Yarnold, C.J., Marston, R.W., et al. (2012). Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease. J. Med. Chem. 55, 1021-1046.
32. Scarpellini, A., Huang, L., Burhan, I., Schroeder, N., Funck, M., Johnson, T.S., and Verderio, E.A. (2014). Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 25, 1013-1027.
33. Schaertl, S., Prime, M., Wityak, J., Dominguez, C., Munoz-Sanjuan, I., Pacifici, R.E., Courtney, S., Scheel, A., and Macdonald, D. (2010). A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J. Biomol. Screen. 15, 478-487.
34. Schoellmann, G., and Shaw, E. (1963). Direct evidence for the presence of histidine in the active center of chymotrypsin. Biochemistry 2, 252-255.
35. Tran, T.T., Mittal, A., Gales, T., Maleeff, B., Aldinger, T., Polli, J.W., Ayrton, A., Ellens, H., and Bentz, J. (2004). Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. J. Pharm. Sci. 93, 2108-2123.
36. Wang, Z., and Griffin, M. (2012). TG2, a novel extracellular protein with multiple functions. Amino Acids 42, 939-949.
37. Wang, Z., and Griffin, M. (2013). The role of TG2 in regulating S100A4-mediated mammary tumour cell migration. PLoS One 8, e57017.
38. Wang, Z., Collighan, R.J., Pytel, K., Rathbone, D.L., Li, X., and Griffin, M. (2012). Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling. J. Biol. Chem. 287, 13063-13083.
39. Wang, Z., Perez, M., Caja, S., Melino, G., Johnson, T.S., Lindfors, K., and Griffin, M. (2013). A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis. Cell Death Dis. 4, e808.
40. Wityak, J., Prime, M.E., Brookfield, F.A., Courtney, S.M., Erfan, S., Johnsen, S., Johnson, P.D., Li, M., Marston, R.W., Reed, L., et al. (2012). SAR development of lysine-based irreversible inhibitors of transglutaminase 2 for Huntington's disease. ACS Med. Chem. Lett. 3, 1024.
41. Zhang, J., Antonyak, M.A., Singh, G., and Cerione, R.A. (2013). A mechanism for the upregulation of EGF receptor levels in glioblastomas. Cell Rep. 3, 2008-2020.